Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $193.2 million.

  • Regenxbio's Non-Current Assets fell 606.75% to $193.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $766.2 million, marking a year-over-year decrease of 1498.2%. This contributed to the annual value of $188.0 million for FY2024, which is 2134.36% down from last year.
  • Regenxbio's Non-Current Assets amounted to $193.2 million in Q3 2025, which was down 606.75% from $207.3 million recorded in Q2 2025.
  • Regenxbio's 5-year Non-Current Assets high stood at $595.1 million for Q4 2021, and its period low was $177.7 million during Q1 2025.
  • In the last 5 years, Regenxbio's Non-Current Assets had a median value of $303.6 million in 2023 and averaged $331.2 million.
  • As far as peak fluctuations go, Regenxbio's Non-Current Assets skyrocketed by 23626.5% in 2021, and later tumbled by 4272.62% in 2023.
  • Over the past 5 years, Regenxbio's Non-Current Assets (Quarter) stood at $595.1 million in 2021, then decreased by 29.88% to $417.3 million in 2022, then crashed by 42.73% to $239.0 million in 2023, then decreased by 21.34% to $188.0 million in 2024, then grew by 2.79% to $193.2 million in 2025.
  • Its Non-Current Assets was $193.2 million in Q3 2025, compared to $207.3 million in Q2 2025 and $177.7 million in Q1 2025.